BDX
Latest Trade
246.71USDChange
0.00(-0.00%)Volume
1,566,365Today's Range
-
248.1452 Week Range
-
284.97As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 246.71 |
---|---|
Open | 247.40 |
Volume | 1,566,365 |
3M AVG Volume | 28.21 |
Today's High | 248.14 |
Today's Low | 244.68 |
52 Week High | 284.97 |
52 Week Low | 197.75 |
Shares Out (MIL) | 290.56 |
Market Cap (MIL) | 71,483.57 |
Forward P/E | 19.29 |
Dividend (Yield %) | 1.35 |
Becton Dickinson Posts Q1 Adjusted Earnings Per Share $4.55
BD Says New Clinical Data Found Evidence That Using Vascular Care Solution Can Help Improve Outcomes For Patients Requiring Peripheral Intravenous Catheters
BD Names CEO Tom Polen As Chairman Of The Board
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.
Industry
Medical Equipment & Supplies
Executive Leadership
Vincent A. Forlenza
Executive Chairman of the Board
Thomas E. Polen
President, Chief Executive Officer, Chief Operating Officer, Director
Christopher R. Reidy
Chief Financial Officer, Executive Vice President, Chief Administrative Officer
David Hickey
President - Life Sciences Segment
Betty D. Larson
Executive Vice President- Human Resources, Chief Human Resources
Price To Earnings (TTM) | 47.29 |
---|---|
Price To Sales (TTM) | 3.93 |
Price To Book (MRQ) | 2.90 |
Price To Cash Flow (TTM) | 19.39 |
Total Debt To Equity (MRQ) | 72.25 |
LT Debt To Equity (MRQ) | 65.21 |
Return on Investment (TTM) | 3.44 |
Return on Equity (TTM) | 3.00 |
A molecular test from Becton Dickinson that detects viruses that cause COVID-19 as well as influenza and produces result in 2-3 hours has been given emergency user authorization by the U.S. health regulator, the company said on Friday.
The U.S. Food and Drug Administration has granted emergency use authorization to a molecular test from Becton Dickinson that can detect viruses that cause COVID-19 as well as influenza and produce results in 2-3 hours, the company said on Friday.
Becton Dickinson on Thursday raised its 2021 profit forecast as the medical device maker expects strong demand for its COVID-19 testing kits to extend into the first half of the year.
Medical technology company Becton Dickinson and Co on Thursday reported a 309% surge in first-quarter profit, fueled by strong demand for its COVID-19 diagnostic tests.
The U.S. government's effort to squeeze more doses from Pfizer Inc's COVID-19 vaccine vials is spurring unanticipated demand for specialized syringes that the world's largest syringe supplier says exceeds existing capacity.
Becton Dickinson and Co on Tuesday forecast first-quarter revenue above Wall Street estimates due to strong demand for its COVID-19 diagnostic tests.
Becton Dickinson and Co will invest about $1.2 billion to boost syringe production, the world's largest needle maker said on Wednesday, as the United States inches closer to making a COVID-19 vaccine available to its people.
Tesla Inc <TSLA.O> Chief Executive Officer Elon Musk questioned the accuracy of COVID-19 tests on Thursday after claiming that results showed he tested positive twice and then negative twice all on the same day.
* BECTON DICKINSON SAYS AWARE OF THE TWEET BY ELON MUSK AND ARE REACHING OUT TO LEARN MORE, CONSISTENT WITH OUR QUALITY MANAGEMENT PROCESS - TWEET
Medical device maker Becton Dickinson and Co <BDX.N> said on Thursday it expects as much as $1.5 billion in sales from its COVID-19 diagnostic test next year, after reporting a quarterly profit that beat Wall Street estimates.
Becton Dickinson and Co on Thursday posted a 16% fall in fourth-quarter profit, as the medical technology company was hurt by patients deferring discretionary procedures due to the COVID-19 pandemic.
Nevada's recent ban on the use of Quidel Corp's Sofia and Becton Dickinson and Co's Veritor point-of-care antigen tests for COVID-19 in long-term care facilities violates federal law, a U.S. government official said on Friday.
U.S. state of Nevada's recent ban on the use of Quidel Corp's Sofia and Becton Dickinson and Co's (BD) Veritor point of care antigen tests in long-term care facilities violates federal law, a U.S. government official said on Friday.
U.S. medical device maker Becton Dickinson and Co said on Wednesday its COVID-19 antigen test kit met the requirements for a launch in Europe.
Becton Dickinson and Co agreed to pay $60 million to resolve allegations by the attorneys general of 48 U.S. states and Washington D.C. that its CR Bard unit concealed the risks of its now-discontinued transvaginal pelvic mesh devices.
Becton Dickinson and Co said on Thursday it has reached a $60 million settlement with the attorneys general of 48 U.S. states and Washington, D.C. to settle litigation related to discontinued pelvic mesh products.
Becton Dickinson and Co said on Thursday it has reached a $60 million settlement with the attorneys general of 48 U.S. states and Washington, D.C. to settle litigation related to discontinued pelvic mesh products.
New York's attorney general on Thursday filed a lawsuit accusing Becton Dickinson and Co's CR Bard unit of concealing the risks of surgical mesh devices.
Becton Dickinson said on Tuesday it is investigating reports from U.S. nursing homes that its rapid coronavirus testing equipment is producing false-positive results.
Becton Dickinson and Co <BDX.N> said on Thursday it was on track to make 1 billion syringes in the next 12-18 months to meet demand for COVID-19 vaccination when approved, as the medical device maker reported quarterly revenue below estimates, sending its shares down nearly...
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.